APA (7th ed.) Citation

Dhungana, R., Prasai, P., Paudel, B., Ranabhat, K., Sapkota, S., & Shrestha, S. (2025). Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Medicine Insights: Oncology, 19, 1. https://doi.org/10.1177/11795549251402955

Chicago Style (17th ed.) Citation

Dhungana, Reechashree, Parikshit Prasai, Bishal Paudel, Kamal Ranabhat, Simit Sapkota, and Sunil Shrestha. "Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Clinical Medicine Insights: Oncology 19 (2025): 1. https://doi.org/10.1177/11795549251402955.

MLA (9th ed.) Citation

Dhungana, Reechashree, et al. "Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Clinical Medicine Insights: Oncology, vol. 19, 2025, p. 1, https://doi.org/10.1177/11795549251402955.